Carrick NewsroomPress Releases

Infinia ML Chief Scientist Shines at 2018 Machine Learning Conference

Durham, NC (Jul 10, 2018) Infinia ML, an advanced machine learning company, announced that its Chief Scientist, Larry Carin, Ph.D., was the second-most published researcher at the Thirty-fifth International Conference on Machine Learning (ICML), which begins today in Stockholm. Carin published seven papers, second only to the eight from Tencent Labs’ Tong Zhang.

ICML, which attracts research from institutions like Google, Stanford, Microsoft, MIT, and Facebook, is widely considered one of the world’s most prestigious machine learning gatherings. Another is the Conference on Neural Information Processing Systems (NIPS), where Carin was the most-published researcher in December 2017.

“To be a top researcher at two top machine learning conferences is extraordinary,” said Infinia CEO Robbie Allen, “and as our clients know, Dr. Carin’s accomplishments aren’t solely academic. He applies cutting-edge machine learning expertise to make real business impact, bridging the gap between the laboratory and the board room.”

Carin’s research lays the groundwork for potential advances in healthcare and general data synthesis. Four of his papers were co-authored with Infinia ML data scientist Ricardo Henao. Another, written with Infinia ML research scientist Hongteng Xu, shows how individual patient records could help hospitals better understand overall infectivity for different diseases. The same technique could help companies examine individual employee history for clues about the company’s contribution to job-hopping.

“We move machine learning forward so that we can move business forward,” said CEO Robbie Allen. “We’re extremely proud of Dr. Carin, Dr. Henao, and Dr. Xu.”

About Infinia ML

Infinia ML is a team of advanced machine learning experts helping enterprise clients reduce costs, increase efficiency, and achieve breakthroughs. Infinia ML serves industries from manufacturing and healthcare to marketing and human resources. The company’s capabilities include natural language processing, recommendation engines, object detection, 3D image modeling, and anomaly detection.

The company is led by CEO Robbie Allen, an experienced AI entrepreneur, Chief Scientist Lawrence Carin, Ph.D., one of the world’s most published machine learning experts and Duke University’s Vice Provost for Research, and Executive Chairman and Carrick Capital Partners Managing Director Mike Salvino. Together, the Infinia ML team has produced 31 patents, 11 books, 7 Ph.D.s, and more than 575 published papers.

Learn more at InfiniaML.com.

Media Contact:

James Kotecki

198208@email4pr.com

202.531.5884

SOURCE: Infinia ML

Related Links
http://InfiniaML.com

About Carrick Capital Partners
Who We Are
A firm of enterprise software and technology enabled services investors and operating executives with substantial experience founding, scaling, and optimizing market leading businesses.
Our Approach
We work with management to identify and improve critical areas of their business - focusing on the priorities that align with our experiences and that will deliver the highest strategic impact in both the short-term and long-run.
Why We Are Different
We have a concentrated number of companies in our portfolio so that we can build substantial relationships with each management team and ensure our firm's commitment to each company's goals.
Latest News
Accolade Logo.jpg
Global Technology Company Apptio Modernizes and Simplifies their Employee Healthcare and Benefits Experience by Bringing Accolade Connect to its Employees and their Family Members
February 20, 2019
Saama Logo
Campbell, CA (February 19, 2019) - Saama Technologies, Inc., a leading data analytics company, today unveiled three new, machine learning-based capabilities that extend the existing functionality of its award-winning Life Science Analytics Cloud (LSAC). Saama announced the addition of these state-of-the-art programs infused with artificial intelligence (AI) -- Virtual Assistant/AI, Operational and Financial Risk Mitigation, and Drug Efficacy and Patient Safety Analytics -- during the 10th Annual Summit for Clinical Ops Executives (SCOPE) in Orlando.
February 19, 2019
Axiom Logo.jpg
New York, NY (February 19, 2019) - Axiom Global Inc. today announced it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The proposed offering is subject to, among other things, completion of the SEC review process and market conditions.
February 19, 2019